{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:12:50Z","timestamp":1790284370752,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T00:00:00Z","timestamp":1586563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T00:00:00Z","timestamp":1586563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasitol Res"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00436-020-06668-6","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T04:02:39Z","timestamp":1586577759000},"page":"1925-1941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Imidazole derivatives as antiparasitic agents and use of molecular modeling to investigate the structure\u2013activity relationship"],"prefix":"10.1007","volume":"119","author":[{"given":"Oluyomi Stephen","family":"Adeyemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiodun Omokehinde","family":"Eseola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Plass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olubunmi","family":"Atolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Sugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwakemi Josephine","family":"Awakan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomilola Debby","family":"Olaolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Obiora","family":"Nwonuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omokolade","family":"Alejolowo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinyomade","family":"Owolabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damilare","family":"Rotimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omowumi Titilola","family":"Kayode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,11]]},"reference":[{"key":"6668_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2174\/1386207320666170110141907","volume":"20","author":"OS Adeyemi","year":"2017","unstructured":"Adeyemi OS, Molina MT, Eseola AO, Fonseca-Berzal C, G\u00f3mez-Barrio A (2017a) New imidazole compounds active against Trypanosoma cruzi. Comb Chem High Throughput Screen 20:20\u201324","journal-title":"Comb Chem High Throughput Screen"},{"key":"6668_CR2","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2147\/IJN.S122178","volume":"12","author":"OS Adeyemi","year":"2017","unstructured":"Adeyemi OS, Murata Y, Sugi T, Kato K (2017b) Inorganic nanoparticles kill Toxoplasma gondii via changes in redox status and mitochondrial membrane potential. Int J Nanomed 12:1647\u20131661","journal-title":"Int J Nanomed"},{"key":"6668_CR3","first-page":"84","volume":"11","author":"OS Adeyemi","year":"2017","unstructured":"Adeyemi OS, Murata Y, Sugi T, Han Y, Kato K (2017c) Modulation of host HIF-1\u03b1 activity and the tryptophan pathway contributes to the anti-Toxoplasma gondii potential of nanoparticles. Biochem Biophys Rep 11:84\u201392","journal-title":"Biochem Biophys Rep"},{"key":"6668_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00436-017-5698-1","volume":"117","author":"OS Adeyemi","year":"2018","unstructured":"Adeyemi OS, Sugi T, Han Y, Kato K (2018a) Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents. Parasitol Res 117:355\u2013363","journal-title":"Parasitol Res"},{"key":"6668_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1166\/jbn.2018.2544","volume":"14","author":"OS Adeyemi","year":"2018","unstructured":"Adeyemi OS, Murata Y, Sugi T, Han Y, Kato K (2018b) Exploring amino acid-capped nanoparticles for selective anti-parasitic action and improved host biocompatibility. J Biomed Nanotechnol 14:847\u2013867","journal-title":"J Biomed Nanotechnol"},{"key":"6668_CR6","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1080\/21691401.2018.1489267","volume":"46","author":"OS Adeyemi","year":"2018","unstructured":"Adeyemi OS, Molefe NI, Awakan OJ, Nwonuma CO, Alejolowo O, Olaolu T, Maimako RF, Suganuma K, Han Y, Kato K (2018c) Metal nanoparticles show potential to restrict Trypanosoma growth. Artif Cells Nanomed Biotechnol 46:S86\u2013S94","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"6668_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.tiv.2018.10.011","volume":"54","author":"OS Adeyemi","year":"2019","unstructured":"Adeyemi OS, Otohinoyi DA, Awakan OJ, Adeyanju AA (2019) Cellular apoptosis of HFF cells by inorganic nanoparticles not susceptible to modulation by Toxoplasma gondii infection in vitro. Toxicol in Vitro 54:280\u2013285","journal-title":"Toxicol in Vitro"},{"key":"6668_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/DDDT.S60973","volume":"11","author":"PH Alday","year":"2017","unstructured":"Alday PH, Doggett JS (2017) Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des Dev Ther 11:273\u2013293. https:\/\/doi.org\/10.2147\/DDDT.S60973","journal-title":"Drug Des Dev Ther"},{"key":"6668_CR9","first-page":"67","volume":"91","author":"O Atolani","year":"2014","unstructured":"Atolani O, Fabiyi OA, Olatunji GA (2014) Isovitexin from Kigelia pinnata, a potential eco-friendly nematicidal agent. Trop Agric 91:67\u201374","journal-title":"Trop Agric"},{"key":"6668_CR10","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1126\/science.162.3858.1146","volume":"162","author":"G Berkelhammer","year":"1969","unstructured":"Berkelhammer G, Asato G (1969) 2-Amino-5-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole: a new antimicrobial agent. Science 162:1146\u20131148","journal-title":"Science"},{"key":"6668_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1191\/0960327106het653oa","volume":"25","author":"JA Castro","year":"2006","unstructured":"Castro JA, de Mecca MM, Bartel LC (2006) Toxic side effects of drugs used to treat Chagas\u2019 disease (American trypanosomiasis). Hum Exp Toxicol 25:471\u2013479","journal-title":"Hum Exp Toxicol"},{"key":"6668_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1590\/S0074-02762002000100001","volume":"97","author":"JR Coura","year":"2002","unstructured":"Coura JR, Castro SL (2002) A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97:3\u201324","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"12","key":"6668_CR13","doi-asserted-by":"publisher","first-page":"7583","DOI":"10.1128\/AAC.03832-14","volume":"58","author":"K Dzitko","year":"2014","unstructured":"Dzitko K, Paneth A, Plech T, Pawe\u0142czyk J, W\u0119gli\u0144ska L, Paneth P (2014 Dec) Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis. Antimicrob Agents Chemother 58(12):7583\u20137585. https:\/\/doi.org\/10.1128\/AAC.03832-14","journal-title":"Antimicrob Agents Chemother"},{"key":"6668_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.dyepig.2010.07.005","volume":"88","author":"AO Eseola","year":"2011","unstructured":"Eseola AO, Li W, Sun WH, Zhang M, Xiao L, Woods JAO (2011) Luminescent properties of some imidazole and oxazole based heterocycles: syntheses, structures, substituent and solvent effects. Dyes Pigm 88:262\u2013273","journal-title":"Dyes Pigm"},{"key":"6668_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1039\/c2nj20880f","volume":"36","author":"AO Eseola","year":"2012","unstructured":"Eseola AO, Adepitan O, G\u00f6rls H, Plass W (2012) Electronic\/substituents influence on imidazole ring donor\u2013acceptor capacities using 1H-imidazo [4,5-f][1,10]phenanthroline frameworks. New J Chem 36:891\u2013902","journal-title":"New J Chem"},{"key":"6668_CR16","doi-asserted-by":"publisher","first-page":"7884","DOI":"10.1039\/C8NJ01265B","volume":"42","author":"AO Eseola","year":"2018","unstructured":"Eseola AO, G\u00f6rls H, Bangesh M, Plass W (2018) ESIPT-capable 2,6-di(1H-imidazol-2-yl)phenols with very strong fluorescent sensing signals towards Cr(III), Zn(II) and Cd(II): molecular variation effects on turn-on efficiency. New J Chem 42:7884\u20137900","journal-title":"New J Chem"},{"key":"6668_CR17","doi-asserted-by":"publisher","first-page":"110398","DOI":"10.1016\/j.mcat.2019.110398","volume":"473","author":"AO Eseola","year":"2019","unstructured":"Eseola AO, G\u00f6rls H, Plass W (2019) Importance of monodentate mono-ligand designs in developing N-stabilized Pd catalysts for efficient ambient temperature C C coupling: donor strengths and steric features. Mol Catal 473:110398. https:\/\/doi.org\/10.1016\/j.mcat.2019.110398","journal-title":"Mol Catal"},{"key":"6668_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ejphar.2004.07.019","volume":"500","author":"K Finlayson","year":"2004","unstructured":"Finlayson K, Witchel HJ, McCulloch J, Sharkey J (2004) Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur J Pharmacol 500:129\u2013142","journal-title":"Eur J Pharmacol"},{"key":"6668_CR19","doi-asserted-by":"publisher","first-page":"e90203","DOI":"10.1371\/journal.pone.0090203","volume":"9","author":"J Flegr","year":"2014","unstructured":"Flegr J, Prandota J, Soviekova M, Israili ZH (2014) Toxoplasmsosis\u2014a global threat. Correlation of latent toxoplasmsosis with specific disease burden in a set of 88 countries. PLoS ONE 9:e90203","journal-title":"PLoS ONE"},{"key":"6668_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.theochem.2004.04.056","volume":"681","author":"N Flores-Holgu\u00edn","year":"2004","unstructured":"Flores-Holgu\u00edn N, Glossman-Mitnik D (2004) CHIH-DFT determination of the molecular structure, infrared and ultraviolet spectra of the antiparasitic drug megazol. J Mol Struct 681:77\u201382","journal-title":"J Mol Struct"},{"key":"6668_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.theochem.2005.02.048","volume":"723","author":"N Flores-Holgu\u00edn","year":"2005","unstructured":"Flores-Holgu\u00edn N, Glossman-Mitnik D (2005) CHIH-DFT determination of the reactivity sites of the antiparasitic drug megazol. J Mol Struct 723:231\u2013234","journal-title":"J Mol Struct"},{"key":"6668_CR22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.bmcl.2013.12.071","volume":"24","author":"C Fonseca-Berzal","year":"2014","unstructured":"Fonseca-Berzal C, Ruiz FAR, Escario JA, Kouznetsov VV, Gomez-Barrio A (2014) In vitro phenotypic screening of 7-chloro-4-amino(oxy) quinoline derivatives as putative anti-Trypanosoma cruzi agents. Bioorg Med Chem Lett 24:1209\u20131213","journal-title":"Bioorg Med Chem Lett"},{"key":"6668_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/(SICI)1097-0169(1999)42:1<36::AID-CM4>3.0.CO;2-G","volume":"42","author":"P Grellier","year":"1999","unstructured":"Grellier P, Sinou V, Garreau-de Loubresse N, Bylen E, Boulard Y, Schrevel J (1999) Selective and reversible effects of vinca alkaloids on Trypanosoma cruzi epimastigote forms: blockage of cytokinesis without inhibition of the organelle duplication. Cell Motil Cytoskeleton 42:36\u201347","journal-title":"Cell Motil Cytoskeleton"},{"key":"6668_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/273506","volume":"2014","author":"Meredith Harrell","year":"2014","unstructured":"Harrell M, Carvounis PE (2014) Current treatment of toxoplasma retinochoroiditis: an evidence-based review. J Ophthalmol 273506. https:\/\/doi.org\/10.1155\/2014\/273506","journal-title":"Journal of Ophthalmology"},{"key":"6668_CR25","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.1128\/AAC.00868-12","volume":"56","author":"ET Kamau","year":"2012","unstructured":"Kamau ET, Srinivasan AR, Brown MJ, Fair MG, Caraher EJ, Boyle JP (2012) A focused small-molecule screen identifies 14 compounds with distinct effects on Toxoplasma gondii. Antimicrob Agents Chemother 56:5581\u20135590","journal-title":"Antimicrob Agents Chemother"},{"key":"6668_CR26","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s00044-017-1805-1","volume":"26","author":"SN Lavorato","year":"2017","unstructured":"Lavorato SN, Duarte MC, Lage DP, Tavares CAP, Coelho EAF, Alves RJ (2017) Synthesis and antileishmanial activity of 1,3-bis(aryloxy)propan-2-amines. Med Chem Res 26:1052\u20131072","journal-title":"Med Chem Res"},{"key":"6668_CR27","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1016\/j.ejmech.2010.05.017","volume":"45","author":"AP Liesen","year":"2010","unstructured":"Liesen AP, de Aquino TM, Carvalho CS, Lima VT, de Araujo JM, de Lima JG, de Faria AR, de Melo EJT, Alves AJ, Alves EW (2010) Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles. Eur J Med Chem 45:3685\u20133691","journal-title":"Eur J Med Chem"},{"key":"6668_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski CA (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1:337\u2013341","journal-title":"Drug Discov Today Technol"},{"key":"6668_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 23:4\u201325","journal-title":"Adv Drug Del Rev"},{"key":"6668_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3\u201326","journal-title":"Adv Drug Deliv Rev"},{"key":"6668_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.sajb.2016.10.005","volume":"110","author":"M Qasim","year":"2017","unstructured":"Qasim M, Abideen Z, Adnan MY, Gulzar S, Gul B, Rasheed M, Khan MA (2017) Antioxidant properties, phenolic composition, bioactive compounds and nutritive value of medicinal halophytes commonly used as herbal teas. S Afr J Bot 110:240\u2013250","journal-title":"S Afr J Bot"},{"key":"6668_CR32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3389\/fcimb.2018.00360","volume":"8","author":"C Rocha-Roa","year":"2018","unstructured":"Rocha-Roa C, Molina D, Cardona N (2018) A perspective on thiazolidinone scaffold development as a new therapeutic strategy for toxoplasmosis. Front Cell Infect Microbiol 8:360. https:\/\/doi.org\/10.3389\/fcimb.2018.00360","journal-title":"Front Cell Infect Microbiol"},{"key":"6668_CR33","first-page":"3","volume":"70","author":"E Rutkowska","year":"2017","unstructured":"Rutkowska E, Pajak K, J\u00f3\u017awiak K (2017) Lipophilicity\u2014methods of determination and its role in medicinal chemistry. Acta Pol Pharm 70:3\u201318","journal-title":"Acta Pol Pharm"},{"key":"6668_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.biopha.2017.07.060","volume":"94","author":"JW Tessmann","year":"2017","unstructured":"Tessmann JW, Buss J, Begnini KR, Berneira LB, Paula FR, de Pereira CMP, Collares T, Seixas FK (2017) Antitumor potential of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-1-Hpyrazoles in human bladder cancer cells. Biomed Pharmacother 94:37\u201346","journal-title":"Biomed Pharmacother"}],"container-title":["Parasitology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-020-06668-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00436-020-06668-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-020-06668-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T23:14:35Z","timestamp":1618096475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00436-020-06668-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,11]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["6668"],"URL":"https:\/\/doi.org\/10.1007\/s00436-020-06668-6","relation":{},"ISSN":["0932-0113","1432-1955"],"issn-type":[{"value":"0932-0113","type":"print"},{"value":"1432-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,11]]},"assertion":[{"value":"4 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}